NEOVACS (EPA:ALNEV) Neovacs S.A.: 2016 Financial Calendar

Directive transparence : information réglementée

29/01/2016 08:00
DGAP-News: Neovacs S.A. / Key word(s): Miscellaneous Neovacs S.A.: 2016 Financial Calendar 29.01.2016 / 08:00 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- PRESS RELEASE 2016 Financial Calendar Paris, January 29, 2016 - NEOVACS (Alternext Paris : ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, annonced today its financial reporting calendar for 2016. Financial publications will be released prior to the opening of the Paris stock exchange. This calendar is indicative and subject to change. - 2015 Full-Year Results: March 7, 2016 - Shareholders' AGM: April 12, 2016 - 2016 Half-Year results: October 14, 2016 About Neovacs Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFN?-Kinoid, an immunotherapy being developed for the indication of lupus. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. For more information on Neovacs, visit www.neovacs.fr Contacts Neovacs / Charlène Masson +33 (0)1 53 10 93 00 cmasson@neovacs.com New Cap / Valentine Brouchot / Pierre Laurent +33 (0)1 44 71 94 94 neovacs@newcap.eu Investor Relations / Financial Communications Germany - MC Services Raimund Gabriel +49-89-21-02-28-30 raimund.gabriel@mc-services.eu Press / U.S. Inquiries - The Ruth Group Joanna Zimmerman / Joseph Green +1-646-536-7012 / 7013 jzimmerman@theruthgroup.com / jgreen@theruthgroup.com --------------------------------------------------------------------------- 29.01.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Neovacs S.A. 3-5, Impasse Reille 75014 Paris France Phone: +33 (0)1 53 10 93 00 Fax: +33 (0)1 53 10 93 03 E-mail: www.neovacs.fr Internet: info@neovacs.fr ISIN: FR0004032746 WKN: A1CVKR Listed: Regulated Unofficial Market in Stuttgart; Open Market in Frankfurt End of News DGAP News Service --------------------------------------------------------------------------- 432927 29.01.2016